AstraZeneca's combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday. The so-called MYSTIC study was the most anticipated clinical experiment in the pharmaceutical industry this year and the news saw the shares tumble more than 16 percent, wiping $14 billion off the company's value in their biggest ever daily fall. The study was seen as key to proving the value of the group's new drug pipeline and its future as an independent company after it spurned a ...
AstraZeneca shares plunge 16% as lung cancer study fails
The two injectable immunotherapy drugs failed to help patients in an advanced lung cancer trial